澳大利亚ASPREE队列提出70岁以上健康成人TSH参考区间
基于ASPREE随机试验中澳大利亚参与者,纳入无心血管病、甲状腺癌、痴呆或危及生命疾病且基线未用甲状腺相关药物的70岁及以上健康社区成人,采用化学发光微粒子免疫法测TSH。共10995人有基线TSH,中位年龄73.9岁,提出TSH参考区间0.34-3.75 mU/L。TSH不随年龄或性别而异,随访至11年区间内TSH与相关疾病结局无关联。
要点
- 70岁以上健康成人TSH参考区间可设为0.34-3.75 mU/L。
- 该人群中TSH水平不随年龄或性别而变化。
- 区间内TSH与甲状腺相关症状及结局风险无关联。
核心结论
- 在70岁及以上初始健康的社区居住成人中,提出TSH参考区间0.34-3.75 mU/L以代表甲状腺功能正常状态。
- 该浓度范围与甲状腺相关症状或结局风险增加无关,支持其临床适用性。
研究设计与样本
- 基于ASPREE随机试验的澳大利亚参与者确定候选参考区间。
- 排除有心血管病、甲状腺癌、痴呆或危及生命疾病史者,以及基线使用任何甲状腺相关药物者。
- TSH采用商用化学发光微粒子免疫法测定,参考区间取基线TSH对数转换数据中间95百分位。
- 采用Cox比例风险回归模型评估随时间变化的疾病发生率以验证参考区间。
- 共10995名参与者有基线TSH测量,中位(IQR)年龄73.9(71.8-77.3)岁。
主要发现
- 提出的TSH参考区间为0.34-3.75 mU/L。
- TSH水平不随年龄或性别而异。
- 基线时甲状腺疾病相关症状与TSH水平无关联。
- 随访至最长11年,参考区间内参与者的基线TSH与相关疾病结局无关联。
关键数值与推荐
- TSH参考区间:0.34-3.75 mU/L(70岁及以上健康成人,化学发光微粒子免疫法)。
- 参考区间取基线TSH对数转换数据的中间95百分位。
- 共10995名参与者有基线TSH测量,中位(IQR)年龄73.9(71.8-77.3)岁。
临床怎么用
- 对70岁及以上健康成人解读TSH时可参考0.34-3.75 mU/L区间。
- 区间内TSH未显示与甲状腺相关症状或结局风险增加相关,支持其用于临床判断。
局限性
- 参考区间基于ASPREE试验的澳大利亚参与者,外推至其他人群需谨慎。
- 原文未报告TSH检测的具体厂家平台细节及参考区间上下限的不确定度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: As thyroid disorders are common amongst the elderly, this study aims to evaluate the reference interval (RI) for thyroid stimulating hormone (TSH) in healthy adults aged 70 years and over. METHODS: A proposed RI was determined from the Australian participants of the ASPirin in Reducing Events in the Elderly (ASPREE) randomised trial. Participants had no history of cardiovascular disease, thyroid cancer, dementia, or life-threatening illnesses. Participants prescribed with any thyroid-related medication at baseline were excluded. TSH levels were measured using a commercial chemiluminescence microparticle immunoassay. The RI was determined using the middle 95th percentile of the logarithmic transformed data of baseline TSH. Cox proportional hazard regression models were used to validate the RI by assessing disease incidence over time. RESULTS: A total of 10,995 participants had baseline TSH measures. Median (IQR) age was 73.9 (71.8-77.3) years. We propose a RI of 0.34-3.75 mU/L. TSH levels did not differ by age or sex. At baseline, there was no association between symptoms associated with thyroid disease and levels of TSH. Over the follow-up period of up to 11 years, no association was seen between baseline TSH levels and relevant disease outcomes for participants within the RI. CONCLUSIONS: From a group of initially healthy, community-dwelling adults aged >=70 years, we propose a RI of TSH to best represent euthyroidism. This concentration was not associated with an increased risk of thyroid related symptoms or outcomes, confirming its appropriateness for clinical use.
引用
- Tran C, Topliss DJ, Schneider HG, et al. Establishing the TSH reference intervals for healthy adults aged over 70 years: the Australian ASPREE cohort study. Clin Chem Lab Med. 2024. PMID: 39358350. doi:10.1515/cclm-2024-0848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。